GW Pharmaceuticals PLC Director Stock Trading Plan - Replacement (9993L)
October 07 2016 - 5:22AM
UK Regulatory
TIDMGWP
RNS Number : 9993L
GW Pharmaceuticals PLC
07 October 2016
Director Stock Trading Plan - Replacement
This announcement replaces the previous RNS announcement 9410L
released at 6:01pm on 6 October 2016. The number of options the
plan provides for exercise and sale was corrected to 372,823
(equivalent to 31,068 American Depositary Shares). Following
exercise of these options Mr Gover will continue to hold 1,057,293
options over Ordinary Shares (equivalent to 88,107 ADSs). All other
information remains unchanged.
London, UK; 7 October 2016: GW Pharmaceuticals plc (Nasdaq:
GWPH, AIM: "GWP," "GW," "the Company" or "the Group"), a
biopharmaceutical company focused on discovering, developing and
commercializing novel therapeutics from its proprietary cannabinoid
product platform, has today been notified that Mr Justin Gover, its
Chief Executive Officer, has established a personal stock trading
plan in accordance both with the guidelines established by Rule
10b5-1 under the U.S. Securities Exchange Act of 1934, as amended,
and the EU Market Abuse Regulation, as well as the Company's
policies with respect to insider sales.
Rule 10b5-1 plans permit directors, officers and other company
insiders to adopt, at times when they are not in possession of
material, non-public information, written plans for trading
securities in a non-discretionary, pre-scheduled manner in the
future. These pre-planned trades can then be executed at a later
date, as spelled out in the plan, without further action by the
director, officer or other company insider and without regard to
any subsequent non-public information the individual might have
received.
Mr Gover's plan provides for the exercise and sale of options
over up to 372,823 Ordinary 0.1p Shares (equivalent to 31,068
American Depository Shares), between 9 December 2016 and 1 April
2017 in order to avoid otherwise adverse personal taxation
implications of non-exercise of these options.
Following exercise of these options, Mr Gover will continue to
hold 1,057,293 options over Ordinary Shares (equivalent to 88,107
ADSs) and will continue to be the beneficial owner of an additional
2,513,759 Ordinary Shares (equivalent to 209,479 ADSs).
The transactions under the plan will be disclosed publicly
through Form 144 and Form 4 filings as required by the U.S.
Securities and Exchange Commission, and by announcement through a
Regulatory Information Service, as required by the EU Market Abuse
Regulation.
For further information, please contact:
GW Pharmaceuticals PLC +44 (0)1980 557 000
Adam George, Company Secretary
Peel Hunt LLP (Nominated Adviser)
James Steel/Oliver Jackson +44 (0) 20 7418 8900
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHEANEXEFKKFEF
(END) Dow Jones Newswires
October 07, 2016 05:22 ET (09:22 GMT)
Gw Pharmaceuticals (LSE:GWP)
Historical Stock Chart
From Nov 2024 to Dec 2024
Gw Pharmaceuticals (LSE:GWP)
Historical Stock Chart
From Dec 2023 to Dec 2024